GlassScriptPhysician profile
Taufiq M Azamy
NPI 1174638811
$587.72
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $86.94 · 2021: $49.94.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $130.90 | 2019 | |
| Sunovion Pharmaceuticals INC. | $101.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $72.31 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $56.06 | 2019-2021 | |
| Allergan, INC. | $50.00 | 2020 | |
| Abbvie INC. | $35.22 | 2021 | |
| Genzyme Corporation | $34.12 | 2019 | |
| Ucb, INC. | $32.10 | 2019 | |
| Neurocrine Biosciences, INC. | $25.90 | 2019-2020 | |
| Biogen, INC. | $18.91 | 2019 | |
| Boston Scientific Corporation | $17.42 | 2019 | |
| Pfizer INC. | $13.56 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taufiq Azamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.